Studies on third dose of COVID-19 vaccine offer ‘hope’ to immunocompromised people
A study published in the New England Journal of Medicine found that a third dose of the Moderna or Pfizer vaccine “significantly improved” its effectiveness in organ transplant recipients who take immunosuppressant drugsBOSTON GLOBE
Research shows that third dose of vaccine may boost immunity for immunocompromised people The COVID-19 vaccine has offered most people the ability to return to their pre-pandemic lives. But people with weakened immune systems, such as transplant recipients
and cancer patients, have had to remain vigilant because their bodies have not responded as robustly to the vaccine.
Now,new research may offer hope that a third dose of the vaccine could boost immunity for the roughly 10.5 million immunocompromised people in the United States, including those with autoimmune diseases.
A study published in the New England Journal of Medicine found that a third dose of the Moderna or Pfizer vaccine “significantly improved” its effectiveness in organ transplant recipients who take immunosuppressant drugsBOSTON GLOBE
Now,new research may offer hope that a third dose of the vaccine could boost immunity for the roughly 10.5 million immunocompromised people in the United States, including those with autoimmune diseases.